

 *Haemostatic defects in
childhood: Principles of
diagnosis and treatment*

*The chain reaction leading to prompt inhibition of bleeding and provide circulating liquid in the case of blood vessel damage.

*Hemostasis

Hemostatic correct operation depends on:

1. plasma and platelet coagulation factors
2. state of the vessel wall
3. blood clotting inhibitors

* Hemostasis

Defects / abnormalities in :

1. Vascular (most common Schoenlein- Henoch disease)
2. Platelets (qualitative/quantitative)
3. Coagulation (deficiency of plasma clotting factors)

* Hemostatic defects

In physical examination:

- * bleeding in the skin and mucous membranes
- * blood hemorrhage to the muscles and joints
- * internal bleeding

* Signs of hemostatic disorder

- *petechiae -not-fading under suppression
changes to 2mm
- *purpura - the result of confluent petechiae
- *bruises (ecchymoses) isolated changes larger
than petechiae

*Signs of hemostatic disorder

Platelets number (below 150 000/mm³ -
trombocytopenia)

Prothrombin time

Activated Partial Thromboplastin Time

Fibrinogen concentration

*Basic laboratory tests

Primary thrombocytopenia:

- Immune/idiopathic thrombocytopenic purpura (ITP)
- Neonatal alloimmune thrombocytopenia
- TAR Syndrome
- Wiskott-Aldrich Syndrome

Primary coagulopathy:

- von Willebrand disease
- Haemophilia
- abnormal platelet function

Hematological causes of bleeding

Secondary thrombocytopenia:

- Cancer
- Aplastic anemia
- DIC- Disseminated Intravascular Coagulation, sepsis
- Drug caused thrombocytopenia
- HUS- haemolytic-uremic syndrome
- hemangiomas
- hypersplenism
- artificial heart valves
- SLE
- HIV

Secondary coagulopathy:

- DIC
- Antykoagulants drugs
- Vit. K deficiency
- Liver failure
- Renal failure
- Anti convulsant therapy during pregnancy-> vit k deficiency

Hematological causes of bleeding

*Platelets disorders

acquired, symptomatic, congenital

- * Acquired (shortened survival time of platelets)
 - immunological, in infancy and early childhood
- * Symptomatic (abnormal production of megakaryocytes) - in hyperplastic diseases or acquired insufficiency of hematopoietic system
- * Congenital (lack of production of megakaryocytes in the bone marrow blood)

* Platelets disorders

Result of:

decreased platelets production

increased their destruction

sequestration

Thrombocytopenia

* Immune/idiopathic
thrombocytopenic
purpura (ITP)

- * Affects young children (> 90% of cases)
- * Acute in onset, usually self-limiting
- * Majority of cases follow vaccinations or viral infections
- * ♂ : ♀ = 1:1
- * 2-6 years of age
- * Antibodies (IgG, IgM) connected to the cell membrane of platelets and lead to their destruction
- * About 10% fail to recover within 6 months → chronic ITP

* ITP - what is it?

- * Acute onset- petechiae, purpura, epistaxis, bleeding gums- 1-4 weeks after viral infection

20,000/ μ l

- * Spontaneous formation of purpura and petechiae
- * Epistaxis
- * Bleeding gums
- * Hematomas in mouth/mucous membranes

<5,000 / μ l

- * Subarachnoid/intracerebral hemorrhage
- * Lower GI bleeding/internal bleeding

Sometimes- adenopathy, hepatosplenomegaly

Elongate bleeding time

* ITP = signs and symptoms

- * Treatment in most cases when PLT number is less than 30 tys./mm³
- * In deep thrombocytopenia:
 - prednison 2-4mg/kg/24 h for 2 weeks
 - or
 - IVIG 1g/kg/ 24 h for 1-2 days
 - or
 - concentrate of human gamma globulin anti-DRh-positive patients

* ITP - treatment

- * splenectomy only for life-threatening bleeding (eg. to CNS)
- * at approx. 80% of children spontaneous withdrawal of the disease within six months of diagnosis
- * serious bleeding (including intracranial) less than 1% of patients

* ITP - treatment and
prognosis

thrombocytopenia - if it takes 6-12 months =
chronic = exclude SLE and HIV infection

dental treatment contraindicated during acute
thrombocytopenia; in chronic thrombocytopenia
- only in a hospital setting: local prevention-
aminocaproic acid, drugs sealing

*ITP - prognosis

***Thrombocytopenia
caused by reduced
production of blood
platelets**

- Megacariopoetic disorders

- * TAR syndrome= thrombocytopenia absent radius
- * Congenital bone marrow aplasia (Fanconi anemia) - anemia, leucopenia, thrombocytopenia
- * Wiskott-Aldrich Syndrome

* Primary
megacariopoethic
disorders



- X-linked recessive disease
- eczema, immune deficiency- hypogammaglobulinemia, T cells dysfunction, thrombocytopenia-> caused by molecular defect
- In peripheral smear- small platelets
- abnormal production of megakaryocytes in the bone marrow and abnormal platelets function
- causal treatment: transplantation of hematopoietic stem cells

* Wiskott-Aldrich Syndrome

- * pancytopenia in bone marrow failure - infiltration of bone marrow by cancer cells or aplastic process
- * some chemotherapeutic agents can selectively destroy megakaryocytes
- * cyanotic congenital heart defects with polycythaemia and thrombocytopenia
- * congenital viral infection (TORCH)
- * acquired viral infections (HIV, EBV, measles virus)
- * some drugs (antiepileptic, antibiotics, heparin, quinidine) can cause thrombocytopenia

* Secondary megacariopoietic disorders

*Thrombocytopenia caused by peripheral platelets destruction

- Immunological mechanisms
- destruction of antibody-coated platelets by cells of the reticuloendothelial system- macrophages

- * due to the sensitization mother to fetus platelet antigens
- * antibodies across the placenta and attack fetal blood platelets
- * maternal ITP may have passive transfer of anti-platelet antibodies, which bind to fetal platelet antigens, resulting in their destruction in the spleen
- * risk of intracranial bleeding in utero and at birth
- * IVIG supply before birth increases the number of platelets in the fetus
- * indicated giving birth by CC
- * neonates with thrombocytopenia $<20 \text{ tys./mm}^3$ may receive IVIG or corticosteroids or get washed maternal platelets

* Neonatal alloimmune thrombocytopenia

*Other diseases

Thrombotic thrombocytopenic purpura(TTP)

- thrombocytopenia, microangiopathic hemolytic anemia, neurological disorders, changes in urine
- Symptoms resulting from the formation of blood clots in the terminal parts of the arterioles and capillaries
- Causes:
- congenital or acquired deficiency of metalloproteinase (ADAMTS13) cleaving von Willebrand factor, or
- the appearance of antibodies to inactivate the enzyme



Thrombotic thrombocytopenic purpura(TTP)

- petechiae and bruising, retinal haemorrhages, bleeding from the gastrointestinal tract; haemolytic anemia
- headaches, confusion, hemiplegia, cranial nerve damage, convulsions
- anemia, increased reticulocytes, fragmentocytes
- elevated serum LDH and bilirubin
- reduced platelet count
- proteinuria, renal impairment
- treatment - plasmapheresis, FFP- fresh frozen plasma

*TTP

*Secondary - exposure to toxins and drugs:

*uremic toxins

*valproic acid

*acetylsalicylic acid

*other NSAIDs

*infection

Primary - cell membrane receptors responsible for platelets adhesion:

Bernard-Soulier syndrome

Glanzmann's thrombasthenia

*Platelets dysfunction

*Serum coagulation disorders

- Congenital and acquired

Factor	Name	Disease name
I	Fibrinogen	A/hipofibrinogenemia
II	Prothrombin	hipoprothrombinemia
III	Tissue factor/ thromboplastin	No disease
IV	Calcium	No disease
V	Proaccerin	Hipoproaccerinemia
VII	Proconvertin	hipoproconvertinemia
VIII	antihemophilic factor	hemophilia A
IX	Christmas factor	hemophilia B
X	Stuart factor	hipostuartemia
XI	plasma trombofactplastin antecedent	hemophilia C
XII	Hagemna's factor	Hageman's defect
XIII	Fibrin stabilizing factor	Congenital XIII factor deficiency

- * Deficiency of clotting factors 8 and 9- severe bleeding disorders (recessive X-linked disorders)

- * von Willebrand disease - the most common congenital bleeding disorder

* Deficiency of clotting factors

- Hemophilia A (factor VIII deficiency) - 1:5000 men
- Hemophilia B (factor IX deficiency) - 1:25 000
- delayed thrombin creation
- The course of disease depends of degree of clotting factor deficiency
- different ways of treatment course depends on the degree of deficiency of clotting factor
- lab. tests: normal bleeding time, normal prothrombin time, normal thrombin time, but prolonged partial thromboplastin time (APTT)

* Hemophilia

- * Concentration VIII and IX factors
- * < 1% of normal range (severe hemophilia) - spontaneous bleeding or after mild injuries to the muscles and joints
- * 1-5% normal range (moderate hemophilia) - signs after stronger trauma
- * > 5% normal range (mild hemophilia) - very strong trauma can cause bleeding ; there are no spontaneous bleeding

* Hemophilia - signs

- * replacement therapy (recombinant coagulation factors); symptomatic and supportive treatment
- * treatment of acute bleeding episodes
- * prevention of bleeding complicating during surgery or tooth extraction

* Hemophilia -treatment


in the case of life- threatening bleeding, the concentration VIII or IX factors should reach 80-100 % of normal range


for mild to moderate bleeding the sufficient range is a concentration of :

factor VIII- 40% normal range,

factor IX 30-40% normal range

* Hemophilia -
treatment

8 factor  1 j.m./kg body mass
increases the 8 factor concentration about 2 %

9 factor  1,5 j.m./kg body mass
increases the 8 factor concentration about 1%

* Hemophilia -
treatment

Factor 8 dose=

Target concentration [%] x body mass [kg] x 0,5

Factor 9 dose=

Target concentration [%] x body mass [kg] x 1,5

* Hemophilia -
treatment

- is a synthetic analog of vasopressin
- Patients with mild to moderate hemophilia A
- It has no effect on the concentration factor 9

***Desmopressin acetate**

- fibrinolysis inhibitor
- It may be useful in controlling bleeding in the mouth
- contraindicated in strokes of blood to the internal organs, hematuria and bleeding to CNS

*Aminocaproic acid

- IgG antibodies directed against infused factor 8 and 9 in patients with their congenital deficiency .

*Inhibitors

- *inhibitor is created in 15 % of patients with factor 8 severe deficiency (less common in patients with factor 9 deficiency)
- *with low concentration of inhibitor -> continuous infusion of factor 8

*Inhibitors

- In case of patients with high range of inhibitor it is necessary to supply the product which passes the blockade
- Recommended drug is recombined 7a factor

*Inhibitors

It may be advantageous - the attempt of immunological tolerance induction by repeated infusions of missing factor with or without immunosuppression.

 **Inhibitors**

- * Prior to surgery (15-30min) patient has to receive factor 8 or 9
- * Antifibrinolytic agents : Exacyl 2 hours before surgery , then for 7 days until adequate gum healing
- * The alveolus fill with spongostan with thrombin and pressure with gauze
- * Diet- liquid- mushy during the healing of the alveolar

* Treatment during teeth
extraction

- * the presence of 1 % of the population
- * inheritance : AD or AR
- * vWF is a protein adhesive : running as a bridge between collagen and platelets and combining with the circulated factor 8 protecting it before removal from plasma

* von Willebrand disease

- * approx. 80% of patients have a form of classical (Type 1 - mild or moderate deficiency of vWF)
- * symptoms: mucocutaneous bleeding, bleeding from the nose, gums, bruises, heavy menstrual periods

* von Willebrand disease

- * Laboratory tests
- * measurement of protein concentration - vWF
- * antigen vWF activity (functional test with ristocetin)

* von Willebrand disease

Treatment:

- desmopressin
- concentrate containing vWF
- Not use crioprecipitat (the risk for viral infection)
- avoid ASA !

von Willebrand disease

- Epsilon-aminocaproic acid
- Tranexamic acid
- Spongostan (sponge fibrin) + thrombin
- The tissue adhesive (fibrinogen with factor XIII and thrombin with Ca ion)

* Symptomatic treatment of
congenital hemorrhagic
diathesis- bleeding disorders

*Vascular coagulation disorders

Allergic purpura

- disease of the small vessels on immune background - increased vascular permeability
- usually after bacterial infections of the throat, often streptococcal
- during chronic infections
- hypersensitivity to milk, fish, crabs

* Allergic purpura
(Schoenlein - Henoch
disease)

- * Skin changes : maculopapular rash, often bleeding around the hocks, on the extensor parts of the lower legs, thighs, buttocks
- * pain and swelling of joints (ankle , knee)
- * abdominal pain, bleeding from the gastrointestinal tract
- * proteinuria, hematuria (glomerular involvement)

* **Schoenlein - Henoch
disease - signs**

- *intestinal motility disorders - possibly intestinal intussusception - obstruction of the gastrointestinal tract
- *no evidence of abnormalities in coagulation tests

***Schoenlein - Henoch
disease - signs**

- * course is usually mild
- * 1 % of the renal lesions may cause damage and renal disease (immune complex deposition IgA)
- * Relapses

* **Schoenlein- Henoch disease**
- course

- * medication sealing vessels (Cyclonamine , Rutinoscorbin , calcium)
- * Bed rest in the acute phase of the disease
- * in cases of more severe corticosteroids p.o. or i.v. 1-2 weeks (parenteral nutrition)
- * The maintaining changes in the kidney are an indication for renal biopsy

* **Schoenlein - Henoch
disease - treatment**



- * 1. Nelson, Pediatria, wyd. I polskie
- * 2. K.Kubicka, W.Kawalec, Pediatria, PZWL, wyd.III
- * 3. Pediatria dla stomatologów pod red. R.Rokickiej-Milewskiej, wyd.IV

* Lectures and references